3rd Annual RAS Targeted Drug Development Summit!

Temas de la conferencia
As promising clinical trial data emerges for KRAS G12C inhibitors and with strong chances of receiving FDA approval this year, the once undruggable RAS family of proteins no longer seem impossible to be cracked. This has undoubtedly resulted in great momentum in the field of oncology to develop RAS targeted therapies that safely, effectively and selectively drug all RAS driven cancers beyond those caused by G12C mutation.

Organizador profesional (PCO)
Hanson Wade

Observaciones
Brochure: https://go.evvnt.com/790905-3?pid=4832

Speakers: Gregory Friberg, Vice President Global Development and Oncology Therapeutic Area Head, Amgen, Susan Yang, Adagrasib Medical Lead, Mirati Therapeutics and more

https://go.evvnt.com/790905-0?pid=4832

Mr. Customer Service